Prime Medicine, Inc.PRMENASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank17
3Y CAGR-66.3%
5Y CAGR-50.9%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-66.3%/yr
Annual compound
5Y CAGR
-50.9%/yr
Recent deceleration
Percentile
P17
Within normal range
vs 5Y Ago
0x
Contraction
Streak
4 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 4.36% |
| 2024 | 15.61% |
| 2023 | 45.50% |
| 2022 | 114.16% |
| 2021 | 340.35% |
| 2020 | 152.56% |
| 2019 | 0.00% |